ATARA BIOTHERAPEUTICS, INC. Accrued Liabilities, Current
ATARA BIOTHERAPEUTICS, INC. (ATRA) had Accrued Liabilities, Current of $2.15 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities, Current $2.15M.
- 2026-03-31: Accrued Liabilities, Current $1.75M.
- 2025-12-31: Accrued Liabilities, Current $1.80M.
- 2025-09-30: Accrued Liabilities, Current $2.55M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $2.15M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.75M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.80M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $2.55M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $4.78M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $9.50M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $6.03M 10-K · filed 2026-03-16 |
| 2024-09-30 | $8.06M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $11.19M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $18.20M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $19.01M 10-K · filed 2025-03-07 |
| 2023-09-30 | $8.30M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $10.65M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $6.76M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $7.43M 10-K · filed 2024-03-28 |
| 2021-12-31 | $5.96M 10-K · filed 2023-02-08 |
| 2020-12-31 | $3.02M 10-K · filed 2022-02-28 |
| 2019-12-31 | $3.90M 10-K · filed 2021-03-01 |
| 2018-12-31 | $5.63M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |